Prognostic Value of Genomic Alterations in Minimal Residual Cancer Cells Purified from the Blood of Breast Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Dec 6

PMID 11104564

Citations 10

Authors

F Austrup

P Uciechowski

C Eder

B Bockmann

B Suchy

G Driesel

S Jackel

I Kusiak

H J Grill

M Giesing

Affiliations

Soon will be listed here.

Abstract

The prognostic value of disseminated tumour cells derived from 353 breast cancer patients was evaluated. Disseminated tumour cells were purified from blood using a newly established method and nucleic acids were subsequently isolated. We investigated genomic imbalances (GI) such as mutation, amplification and loss of heterozygosity of 13 tumour suppressor genes and 2 proto-oncogenes using DNA from isolated minimal residual cancer cells. Significant correlations were found between genomic alterations of the DCC - and c-erbB-2 genes in disseminated breast cancer cells and actuarial relapse-free survival. Furthermore, increasing numbers of genomic imbalances measured in disseminated tumour cells were significantly associated with worse prognosis of recurrent disease. Logistic regression and Cox multivariate analysis led to the identification of genomic imbalances as an independent prognostic factor. Determination of disseminated tumour cells by genotyping of oncogenes and tumour suppressor genes seems not only to be a useful adjunct in follow up of carcinoma patients but provides also valuable additional individualized prognostic and predictive information in breast cancer patients beyond the TNM system.

Citing Articles

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues.

Bohers E, Viailly P, Jardin F Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34205827 PMC: 8234829. DOI: 10.3390/ph14060596.

Semaphorin 3F and Netrin-1: The Novel Function as a Regulator of Tumor Microenvironment.

Nakayama H, Kusumoto C, Nakahara M, Fujiwara A, Higashiyama S Front Physiol. 2018; 9:1662.

PMID: 30532711 PMC: 6265511. DOI: 10.3389/fphys.2018.01662.

[Blood-based Tumor Markers in Lung Cancer].

Zhou C Zhongguo Fei Ai Za Zhi. 2015; 18(12):770-80.

PMID: 26706955 PMC: 6015179. DOI: 10.3779/j.issn.1009-3419.2015.12.10.

NY-ESO-1 antibody as a novel tumour marker of gastric cancer.

Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J Br J Cancer. 2013; 108(5):1119-25.

PMID: 23403818 PMC: 3619069. DOI: 10.1038/bjc.2013.51.

Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein.

Shimizu A, Nakayama H, Wang P, Konig C, Akino T, Sandlund J J Biol Chem. 2012; 288(4):2210-22.

PMID: 23195957 PMC: 3554894. DOI: 10.1074/jbc.M112.397398.

References

Engel H, Kleespies C, Friedrich J, Breidenbach M, Kallenborn A, Schondorf T . Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics. Br J Cancer. 1999; 81(7):1165-73. PMC: 2374326. DOI: 10.1038/sj.bjc.6690825. View

Brandt B, Roetger A, Heidl S, Jackisch C, Lelle R, Assmann G . Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer. 1998; 76(6):824-8. DOI: 10.1002/(sici)1097-0215(19980610)76:6<824::aid-ijc10>3.0.co;2-2. View

Al-Mehdi A, Tozawa K, Fisher A, Shientag L, Lee A, Muschel R . Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 1999; 6(1):100-2. DOI: 10.1038/71429. View

Nemoto T, Vana J, Bedwani R, Baker H, McGregor F, Murphy G . Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980; 45(12):2917-24. DOI: 10.1002/1097-0142(19800615)45:12<2917::aid-cncr2820451203>3.0.co;2-m. View

McGee T, Yandell D, Dryja T . Structure and partial genomic sequence of the human retinoblastoma susceptibility gene. Gene. 1989; 80(1):119-28. DOI: 10.1016/0378-1119(89)90256-4. View

Hauge X, Evans G, Litt M . Dinucleotide repeat polymorphism at the D11S528 locus. Nucleic Acids Res. 1991; 19(8):1964. PMC: 328155. DOI: 10.1093/nar/19.8.1964. View

van Leeuwen C, Tops C, Breukel C, van der Klift H, Fodde R, Khan P . CA repeat polymorphism at the D5S299 locus linked to adenomatous polyposis coli (APC). Nucleic Acids Res. 1991; 19(20):5805. PMC: 329022. DOI: 10.1093/nar/19.20.5805-a. View

Huang Y, Boynton R, Blount P, Silverstein R, Yin J, Tong Y . Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992; 52(23):6525-30. View

Cawkwell L, Bell S, Lewis F, Dixon M, Taylor G, Quirke P . Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer. 1993; 67(6):1262-7. PMC: 1968523. DOI: 10.1038/bjc.1993.236. View

10.

Hardingham J, Kotasek D, Farmer B, Butler R, Mi J, Sage R . Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 1993; 53(15):3455-8. View

11.

Chen P, Lin S, Wang C, Chen Y, Chen T, Chang J . "Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. Clin Chem. 1993; 39(10):2186-91. View

12.

Kirchweger R, Zeillinger R, Schneeberger C, SPEISER P, Louason G, Theillet C . Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer. 1994; 56(2):193-9. DOI: 10.1002/ijc.2910560208. View

13.

Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millasseau P . The 1993-94 Généthon human genetic linkage map. Nat Genet. 1994; 7(2 Spec No):246-339. DOI: 10.1038/ng0694supp-246. View

14.

Villuendas R, Sanchez-Beato M, Martinez J, Saez A, Martinez-Delgado B, Garcia J . Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol. 1998; 153(3):887-97. PMC: 1853011. DOI: 10.1016/S0002-9440(10)65630-1. View

15.

Naume B, Borgen E, Nesland J, Beiske K, Gilen E, Renolen A . Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer. 1998; 78(5):556-60. DOI: 10.1002/(sici)1097-0215(19981123)78:5<556::aid-ijc5>3.0.co;2-g. View

16.

Leitzel K, Lieu B, Curley E, Smith J, Chinchilli V, Rychlik W . Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor. Clin Cancer Res. 1998; 4(12):3037-43. View

17.

Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P . Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet. 1999; 110(2):94-102. DOI: 10.1016/s0165-4608(98)00205-2. View

18.

Soria J, Gauthier L, Raymond E, Granotier C, Morat L, Armand J . Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 1999; 5(5):971-5. View

19.

Offner S, Schmaus W, Witter K, Baretton G, Schlimok G, Passlick B . p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci U S A. 1999; 96(12):6942-6. PMC: 22021. DOI: 10.1073/pnas.96.12.6942. View

20.

Hampl M, Hampl J, Reiss G, Schackert G, Saeger H, Schackert H . Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome. Clin Cancer Res. 1999; 5(6):1417-25. View